Florricks Lifecare, a leading research-driven pharmaceutical company in India, involved in R&D, production, and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Forms across multiple therapeutic areas, including critical care and oncology, has entered into strategic partnerships with two prominent companies in Hong Kong and Europe, marking a total investment of $95 million.
The partnerships aim to leverage Florricks Lifecare's expertise in cutting-edge pharmaceutical solutions, bolstering its presence and capabilities in these critical regions.
Dr Salim Shaikh, Managing Director & CEO of Florricks Lifecare stated, "With this significant investment, the company is set to make substantial strides in research, development, and production, ensuring the highest standards of quality and safety. Established with a vision to make a difference in healthcare, Florricks Lifecare has grown to become a recognised leader in sourcing and supplying Active Pharmaceutical Ingredients (APIs) and intermediates to pharmaceutical manufacturers and healthcare providers worldwide."
Lalit Singh, Executive Director of Florricks Lifecare, stated, "Florricks Lifecare’s hybrid supplying and global sourcing model for ingredients and raw materials delivers the most flexible and reliable solutions for our customers’ unique manufacturing requirements. We offer the flexibility to supply or source difficult-to-find ingredients and materials, supported by industry-leading standards of quality documentation and regulatory compliance. This investment will propel Florricks Lifecare to further expand our global expansion."
